ClinicalTrials.gg
RecruitingNCT07174583Updated Jul 9, 2026

A Study of IDE849 in Patients With DLL3 Expressing Tumors Including Small Cell Lung Cancer

A Phase 1/2 interventional study of IDE849 and durvalumab in Small-cell Lung Cancer, Neuroendocrine Carcinomas and Solid Tumor Show to Express DLL3, sponsored by IDEAYA Biosciences. Recruiting at 13 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-07-09.

Sponsored by IDEAYA Biosciences · Phase 1/2, Interventional, and Treatment

From the registry’s dates

  • Started Oct 2025; still recruiting 1 year 1 month later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
262
Allocation
Non-randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-18

Among 631 studies in Small Cell Lung Carcinoma with a site in United States — 112 open to participants now, 183 under way, 26 of them phase 3. Small Cell Lung Carcinoma · United States.

Planned enrollment
87th of 552
262 · median 55
Started
2025
with 39 others
Phase 1/2
113 of 631
32 open now
Primary completion
2029-07
later than 145 of 182 live
Registered
592nd of 631
by date

Among the 631 studies in Small Cell Lung Carcinoma with a site in United States, this one is the 87th largest by planned enrollment of the 552 interventional ones that give a count, is one of 40 that started in 2025, is one of 113 in phase 1/2, reaches primary completion later than 145 of the 182 other live ones, and was the 592nd registered.

Small Cell Lung Carcinoma

1,303 studies on the registry are indexed under Small Cell Lung Carcinoma; 366 are open to participants now.

Browse Small Cell Lung Carcinoma studies →

Open to participants now

112 of the 631 studies in Small Cell Lung Carcinoma with a site in United States are open now. Recruiting first, the newest first:

107 more — sign in →

All 112 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 266 Small Cell Lung Carcinoma studies recruiting now, 176 (66%) set no upper age limit and 66 (25%) stop at 75 or younger; 3 take children under 18; 8 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 631 studies in Small Cell Lung Carcinoma with a site in United States, or all of them as a file.
02

Study summary

This is Phase 1/2, multicenter, clinical study to evaluate the safety, efficacy, PK, and immunogenicity of IDE849 in subjects with DLL3-expressing tumors including SCLC.

Read the detailed description

This multicenter, open-label, Phase 1/2 study is designed to further characterize the safety, tolerability, pharmacokinetics (PK), immunogenicity, and preliminary anti-tumor activity of IDE849, an anti-DLL3 antibody-drug conjugate, alone and in combination with durvalumab or IDE161, in subjects with DLL3-expressing tumors including small-cell lung cancer (SCLC), high-grade neuroendocrine carcinomas (NEC), and other DLL3-positive solid tumors.

Part 1 (Dose Escalation):

Part 1A will evaluate IDE849 monotherapy, and Part 1B will evaluate IDE849 in combination with durvalumab or IDE161. This phase is designed to assess safety and tolerability, identify dose-limiting toxicities (DLTs), and determine the maximum tolerated dose (MTD) and recommended dose for expansion (RDE), in subjects with extensive-stage SCLC, high-grade NEC, or other DLL3-expressing tumors.

Part 2 (Dose Expansion):

Part 2 further will evaluate IDE849 alone or in combination at selected dose levels to characterize safety, PK, immunogenicity, and preliminary anti-tumor activity in defined cohorts of subjects with extensive-stage SCLC, high-grade NEC, or other DLL3-expressing tumors.

03

Conditions studied

  • Small-cell Lung Cancer
  • Neuroendocrine Carcinomas
  • Solid Tumor Show to Express DLL3

Keywords

  • IDE849
  • Small Cell Lung Cancer
  • SCLC
  • anti-DLL3 immunoglobulin G1 monoclonal antibody
  • DLL3
  • Neuroendocrine Carcinomas
  • NEC
  • durvalumab
  • IDE161
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Are willing to participate in this clinical study, understand the study procedures, and are able to sign the written ICF.
  2. Subjects with or cytologically confirmed ES- SCLC, neuroendocrine carcinoma (NEC), DLL3+ solid tumors, are eligible per protocol. Subjects must have radiologically progressed or recurred after previous standard treatment.

    For SCLC, this includes platinum-based therapy and programmed death-1/programmed death-ligand 1 inhibitors (except for subjects who refuse, or are judged by the Investigator to be unsuitable, or were intolerant to immunotherapy and chemotherapy may enroll to receive monotherapy or IDE161 combination.

  3. Subjects with NEC, this includes

    • High-grade gastroenteropancreatic NEC
    • NEC of the prostate
    • Small cell NEC of any other organ
    • Merkel cell carcinoma
    • Transformed non-small cell adenocarcinoma of the lung (including but not limited to epidermal growth factor receptor or Kirsten rat sarcoma viral oncogene homolog mutated adenocarcinoma of the lung post progression on targeted therapies
    • Any other NEC that does not meet any of the indications noted above.
  4. Subjects with other solid tumors demonstrated to express moderate/high expression of DLL3 including melanoma, Grade 3 gastrointestinal and pancreatic NETs, and pulmonary carcinoids.

    • metastatic melanoma
  5. Subjects will be required to provide blood/tumor tissue samples for biomarker testing.
  6. Have at least 1 according to (RECIST) version 1.1.
  7. Have (ECOG) Performance Status (PS) score of 0 or 1.
  8. Have > 3 months.
  9. Have adequate bone marrow and organ function within 7 days of the first dose (no use of any blood components and/or cell growth factors within 14 days prior to the start of the study treatment).
  10. Women of (WOCBP) must agree to take highly effective measures from signing of consent through 8 months after the last dose of IDE849; men with partners of child-bearing potential must use effective contraception through 5 months after the last dose.

Exclusion criteria

Exclusion Criteria:

  1. Have mixed SCLC and NSCLC histology are not allowed (SCLC with components of large cell NEC are eligible). Participants with limited stage SCLC are ineligible.
  2. Subjects with locally untreated (radiotherapy or surgery) or active central nervous system (CNS) tumor .
  3. Have had other within 2 years prior to the first dose, except adequately treated carcinoma in situ (cervical, breast, or other), basal cell or squamous cell skin cancer, localized prostate cancer after curative therapy with no recurrence, or papillary thyroid cancer after curative resection; other prior or concurrent malignancies may be eligible with Medical Monitor review and approval.
  4. Have uncontrolled tumor-associated pain.
  5. Have severe cardiovascular and cerebrovascular disease
  6. Have history of bleeding within 3 months before the first study dose.
  7. Have history of interstitial pneumonitis during previous treatment; current noninfectious pneumonitis requiring therapy; known or suspected interstitial pneumonitis as seen on screening imaging; other moderate to severe lung diseases seriously affecting respiratory function within 3 months before the first dose, including, but not limited to, idiopathic pulmonary fibrosis and organizing pneumonia/obliterative bronchiolitis.
  8. Have history of immunodeficiency, with a positive (HIV) test at screening (HIV antibody positive and HIV-RNA above the lower limit of detection of the analytical method).
  9. Subjects with known or suspected viral hepatitis.
  10. Have a history of active tuberculosis within 1 year before enrollment.
  11. For participants enrolling to receive the combination with durvalumab, must not be deemed by the Investigator to be unsuitable to receive immunotherapy, or have had any prior intolerance to /PD-L1 inhibitor therapy, or have had any prior Grade 2 or higher myocarditis or any other Grade 3 or higher immune-related AE. If the participant has had a prior immune-related AE, must have recovered to Grade \< 1.
  12. For participants enrolling to receive the combination with IDE161, must not have had prior GI or upper bowel removal or any other gastrointestinal disorder or defect (eg, malabsorption disorder such as Crohn's disease or ulcerative colitis), that would interfere with absorption of IDE161.
  13. For patients receiving a combination with carboplatin, be deemed by the Investigator to be unsuitable to receive platinum-based chemotherapy, or have had intolerance to platinum-based chemotherapy
  14. Have received chemotherapy within 3 weeks of first dose of IMP; immunotherapy or biologic targeted antitumor treatments within 2 weeks before the first dose of IMP; for small molecule treatments within 2 weeks before the first dose of the IMP or within 5 half lives of the drug (whichever is longer); other products within 4 weeks or within 5 half-lives of the drug (whichever is longer) unless, in the opinion of the Investigator and Sponsor, the medication will not interfere with the study. Participants who received an immunotherapy agent (eg, PD-1/PD-L1 inhibitor) immediately prior to study enrollment must have documented radiologic disease progression as per the Investigator prior to the first dose of IMP
  15. Administration of any of the following:

    • Use of drugs that are inhibitors of P-gp, BCRP, and OATPIB1/OATP1B3
    • Use of drugs with known risk of within 5 half-lives of their administration.
  16. For participants enrolling to receive the combination with IDE161:

    • Use of drugs of narrow therapeutic index that are sensitive substrates of MATE2-K, BCRP, and P-gp
    • Use of known moderate and strong /5 inducers and inhibitors is not permitted
    • Administration of PPIs
    • Use of an H2 blocking agent
    • Use of a local antacid
    • Use of drugs with a known risk of QT prolongation
  17. Have prior treatment with DLL3 ADC with a Topo1 inhibitor payload (except for participants enrolling to receive the IDE161 combination).
  18. For participants enrolling to receive the combination with durvalumab, have history of prior intolerance to PD-1/PD-L1 inhibitors.
  19. Have received > 30 Gy of chest radiotherapy within 8 weeks prior to the first dose of the IMP, > 30 Gy of non-chest radiotherapy within 14 days prior to the first dose (subjects who have completed radiotherapy for within 14 days prior to the first dose can be enrolled and palliative radiotherapy for other sites of ≤ 30 Gy is allowed if completed more than 14 days prior to the first dose).
  20. Have undergone major surgery or experienced significant trauma within 4 weeks prior to the first dose.
  21. Female subjects who are pregnant, lactating, or planning to become pregnant during the study period to 8 months after the last dose of the IMP.
Terms in these criteria, in plain language(17)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

PD-1, PD-L1 and checkpoint inhibitors

PD-1, PD-L1 and CTLA-4 are proteins that act as brakes on the immune system. Checkpoint inhibitors, such as pembrolizumab or nivolumab, block them so the immune system can attack a cancer.

PD-L1 can also be measured in a tumor sample. Some scores count stained tumor cells only (TPS); others also count certain immune cells (CPS). The study names the score and the minimum it uses.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

CYP3A (CYP3A4) inhibitors and inducers

CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.

Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
262 participants (estimated)

Study arms

  • Experimental
    Part 1A IDE849 Monotherapy (Dose Escalation)

    Successive cohorts of participants will be treated with escalating doses of IDE849 until the maximum tolerated dose and dose for expansion are determined

    Drug: IDE849

  • Experimental
    Part 1B IDE849 + durvalumab, or IDE849 + durvalumab + carboplatin (Dose Escalation)

    Multiple doses of IDE849 will be tested in combination with durvalumab or in combination with durvalumab + carboplatin to identify the optimal combination dose.

    Drug: IDE849 · Drug: durvalumab · Drug: Carboplatin

  • Experimental
    Part 1B IDE849 + IDE161 (Dose Escalation)

    Multiple doses of IDE849 will be tested in combination with IDE161 to identify the optimal combination dose.

    Drug: IDE849 · Drug: IDE161

  • Experimental
    Part 2 IDE849 Monotherapy RDE 1 for SCLC (Dose Expansion)

    Chosen monotherapy doses of IDE849 will be tested in additional participants.

    Drug: IDE849

  • Experimental
    Part 2 IDE849 Monotherapy RDE 2 for SCLC (Dose Expansion)

    Chosen monotherapy doses of IDE849 will be tested in additional participants

    Drug: IDE849

  • Experimental
    Part 2 IDE849 Monotherapy for NEC (Dose Expansion)

    Chosen monotherapy doses of IDE849 will be tested in additional participants.

    Drug: IDE849

  • Experimental
    Part 2 IDE849 + durvalumab (Dose Expansion)

    Chosen combination dose of IDE849 + durvalumab will be tested in additional participants.

    Drug: IDE849 · Drug: durvalumab

  • Experimental
    Part 2 IDE849 + durvalumab + carboplatin (Dose Expansion)

    Chosen combination dose of IDE849 + durvalumab + carboplatin will be tested in additional participants.

    Drug: IDE849 · Drug: durvalumab · Drug: Carboplatin

  • Experimental
    Part 2 IDE849 + IDE161 (Dose Expansion)

    Chosen combination dose of IDE849 + IDE161 will be testing in additional participants

    Drug: IDE849 · Drug: IDE161

Interventions

  • DrugIDE849

    IV administration

  • IV administration

    Also known as: durvalumab Injection [Imfinzi]

  • DrugIDE161

    oral administration

  • IV administration

06

What researchers measure

Primary outcomes

  1. Part 1A: Safety and Tolerability of IDE849 (Monotherapy)

    Incidence of dose-limiting toxicities, incidence and severity AEs and SAEs as measured by CTCAE V5.0.

    Time frame: approximately 4 years total study duration

  2. Part 1B: Safety and Tolerability of IDE849 in Combination with durvalumab or IDE161

    Incidence of dose-limiting toxicities, incidence and severity AEs and SAEs as measured by CTCAE V5.0.

    Time frame: approximately 4 years total study duration

  3. Part 2: Safety and Tolerability of IDE849 (Monotherapy Dose Expansion)

    Incidence and severity and relationship of AEs and SAEs as measured by CTCAE V5.0

    Time frame: approximately 4 years total study duration

  4. Part 2: Safety and Tolerability of IDE849 in Combination with durvalumab or IDE161 or durvalumab + carboplatin (Dose Expansion)

    Incidence and severity and relationship of AEs and SAEs graded as measured by CTCAE V 5.0.

    Time frame: approximately 4 years total study duration

  5. Part 2: Objective Response Rate (ORR) and Investigator Assessment of IDE849 ORR per RECIST 1.1

    ORR per RECIST v1.1, defined as the proportion of subjects with a Complete Response (CR) or Partial Response (PR) as assessed by the Investigator.

    Time frame: approximately 4 years total study duration

  6. Part 2: Duration of Response (DOR) and Investigator Assessment of IDE849 DOR per RECIST 1.1

    DOR per RECIST v1.1, defined as the time from the first documented Complete Response (CR) or Partial Response (PR) to disease progression or death, whichever occurs first, as assessed by the Investigator.

    Time frame: approximately 4 years total study duration

Secondary outcomes

  1. Part 1 and Part 2: Disease Control Rate (DCR) and Investigator Assessment of IDE849 DCR per RECIST 1.

    Time frame: approximately 4 years total study duration

  2. Part 2: Progression-Free Survival (PFS) PFS per RECIST1.1 PFS per RECIST1.1.

    Time frame: approximately 4 years total study duration

  3. Part 2: Overall Survival (OS)

    Overall Survival (OS) defined as the time from first dose of IDE849 to death due to any cause

    Time frame: approximately 4 years total study duration

  4. Part 1 and Part 2: Pharmacokinetics (PK) of IDE849 and in combination with durvalumab, durvalumab + carboplatin, and IDE161 Blood concentrations and PK parameters.

    Time frame: approximately 4 years total study duration

  5. Part 1 and Part 2: Dose-Exposure Response of IDE849 and in combination with durvalumab, durvalumab + carboplatin, and IDE161 Relationship between IDE849 dose level and systemic exposure based on plasma concentration data and pharmacokinetic parameters

    Time frame: approximately 4 years total study duration

  6. Part 1 and Part 2: Dose-Exposure Response of IDE849 and in combination with durvalumab and IDE161 Relationship between IDE849 dose level and systemic exposure based on plasma concentration data and pharmacokinetic parameters

    Time frame: approximately 4 years total study duration

07

Study locations

13 of 13 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Oct 2025 (actual). Primary completion is estimated for Jul 2029, 45 months after the start.

Of 71 industry-sponsored phase 1/2 interventional studies under Small Cell Lung Carcinoma, half reached primary completion within 54 months of starting (the median), counting those still running; a quarter within 43 and three quarters within 74. This study's planned 45 months is below that.

Counting every sponsor, half of 98 studies reached it within 54 months; a quarter within 44 and three quarters within 97.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 11, 2025
First posted
Sep 16, 2025
StartActual
Oct 14, 2025
Primary completionEst.
Jul 2029
CompletionEst.
Jul 2029
Last update
Jul 9, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 9, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07174583
Lead sponsor
IDEAYA Biosciences
Responsible party
Sponsor
First posted
Sep 16, 2025
Start date
Oct 14, 2025
Primary completion
Jul 2029 (estimated)
Completion
Jul 2029 (estimated)
Last update
Jul 9, 2026

Study contacts

IDEAYA Clinical Trials
Contact
IDEAYAClinicalTrials@ideayabio.com
+1-855-433-2246

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion